about | Maps & Directions | contact | admissions | faculty | alumni & development | library | Tech Support Center | dean's office | Policies & Procedures

FAculty directory

Back to alphabetical index


Jaroslav Jelinek, MD, PhD


Research Associate Professor, Fels Institute for Cancer Research

and Molecular Biology

Telephone:  215-707-7312

Fax:  215-707-5963

Email: jjelinek@temple.edu


Fels Institute for Cancer Research and Molecular Biology


Educational Background:


PhD in Medical Sciences, Charles University 1st School in Medicine, Prague, Czech Republic, 1985


Return to top



Research Interests:


Cancer Epigenetics

Return to top




Recent Medically Related Publications, Obtained from PubMed (Click on PubMed ID to view abstract)

25455458. van Esterik JC, Vitins AP, Hodemaekers HM, Kamstra JH, Legler J, Pennings JL, Steegenga WT, Lute C, Jelinek J, Issa JP, Dollé ME, van der Ven LT, Liver DNA methylation analysis in adult female C57BL/6JxFVB mice following perinatal exposure to bisphenol A. Toxicol Lett 232:1(293-300)2014 Oct 17

25024751. Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Aldaz M, Issa JP, Kurzrock R, Wistuba II, Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. Clin Epigenetics 6:1(13)2014

24875481. Jin C, Lu Y, Jelinek J, Liang S, Estecio MR, Barton MC, Issa JP, TET1 is a maintenance DNA demethylase that prevents methylation spreading in differentiated cells. Nucleic Acids Res 42:11(6956-71)2014 Jun

24875133. Plimack ER, Desai JR, Issa JP, Jelinek J, Sharma P, Vence LM, Bassett RL, Ilagan JL, Papadopoulos NE, Hwu WJ, A phase I study of decitabine with pegylated interferon a-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations. Invest New Drugs 32:5(969-75)2014 Oct

24670685. Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP, Lee AV, Chen J, Shea MJ, Santen RJ, Gannon F, Kangaspeska S, Jelinek J, Issa JP, Richer JK, Elias A, McIlroy M, Young LS, Davidson NE, Schiff R, Li W, Oesterreich S, Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med 6:229(229ra41)2014 Mar 26

24414704. Maegawa S, Gough SM, Watanabe-Okochi N, Lu Y, Zhang N, Castoro RJ, Estecio MR, Jelinek J, Liang S, Kitamura T, Aplan PD, Issa JP, Age-related epigenetic drift in the pathogenesis of MDS and AML. Genome Res 24:4(580-91)2014 Apr

24401732. Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Issa JP, Wistuba II, Kurzrock R, Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. Clin Epigenetics 6:1(2)2014 Jan 9

24385213. Tahara T, Yamamoto E, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, An B, Shureiqi I, Toyota M, Kondo Y, Estécio MR, Issa JP, Fusobacterium in colonic flora and molecular features of colorectal carcinoma. Cancer Res 74:5(1311-8)2014 Mar 1

24367927. Malouf GG, Taube JH, Lu Y, Roysarkar T, Panjarian S, Estecio MR, Jelinek J, Yamazaki J, Raynal NJ, Long H, Tahara T, Tinnirello A, Ramachandran P, Zhang XY, Liang S, Mani SA, Issa JP, Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. Genome Biol 14:12(R144)2013 Dec 24

24211491. Tahara T, Yamamoto E, Madireddi P, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, Kondo Y, Toyota M, Issa JP, Estécio MR, Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators. Gastroenterology 146:2(530-38.e5)2014 Feb

23943784. Tahara T, Maegawa S, Chung W, Garriga J, Jelinek J, Estécio MR, Shibata T, Hirata I, Arisawa T, Issa JP, Examination of whole blood DNA methylation as a potential risk marker for gastric cancer. Cancer Prev Res (Phila) 6:10(1093-100)2013 Oct

23249680. Yamazaki J, Estecio MR, Lu Y, Long H, Malouf GG, Graber D, Huo Y, Ramagli L, Liang S, Kornblau SM, Jelinek J, Issa JP, The epigenome of AML stem and progenitor cells. Epigenetics 8:1(92-104)2013 Jan

23075513. Jelinek J, Liang S, Lu Y, He R, Ramagli LS, Shpall EJ, Estecio MR, Issa JP, Conserved DNA methylation patterns in healthy blood cells and extensive changes in leukemia measured by a new quantitative technique. Epigenetics 7:12(1368-78)2012 Dec 1

22395470. Yamazaki J, Taby R, Vasanthakumar A, Macrae T, Ostler KR, Shen L, Kantarjian HM, Estecio MR, Jelinek J, Godley LA, Issa JP, Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 7:2(201-7)2012 Feb

22219169. Raynal NJ, Si J, Taby RF, Gharibyan V, Ahmed S, Jelinek J, Estécio MR, Issa JP, DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res 72:5(1170-81)2012 Mar 1

22138693. Challen GA, Sun D, Jeong M, Luo M, Jelinek J, Berg JS, Bock C, Vasanthakumar A, Gu H, Xi Y, Liang S, Lu Y, Darlington GJ, Meissner A, Issa JP, Godley LA, Li W, Goodell MA, Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet 44:1(23-31)2011 Dec 4

22132162. Konishi K, Watanabe Y, Shen L, Guo Y, Castoro RJ, Kondo K, Chung W, Ahmed S, Jelinek J, Boumber YA, Estecio MR, Maegawa S, Kondo Y, Itoh F, Imawari M, Hamilton SR, Issa JP, DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis. PLoS One 6:11(e27889)2011

21858090. Qin T, Castoro R, El Ahdab S, Jelinek J, Wang X, Si J, Shu J, He R, Zhang N, Chung W, Kantarjian HM, Issa JP, Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One 6:8(e23372)2011

21853109. Watanabe Y, Castoro RJ, Kim HS, North B, Oikawa R, Hiraishi T, Ahmed SS, Chung W, Cho MY, Toyota M, Itoh F, Estecio MR, Shen L, Jelinek J, Issa JP, Frequent alteration of MLL3 frameshift mutations in microsatellite deficient colorectal cancer. PLoS One 6:8(e23320)2011

21760961. Jelinek J, Gharibyan V, Estecio MR, Kondo K, He R, Chung W, Lu Y, Zhang N, Liang S, Kantarjian HM, Cortes JE, Issa JP, Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One 6:7(e22110)2011

21586619. Chung W, Bondaruk J, Jelinek J, Lotan Y, Liang S, Czerniak B, Issa JP, Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev 20:7(1483-91)2011 Jul

21459801. Pathiraja TN, Shetty PB, Jelinek J, He R, Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP, Oesterreich S, Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res 17:12(4177-86)2011 Jun 15

20716667. Estécio MR, Gallegos J, Vallot C, Castoro RJ, Chung W, Maegawa S, Oki Y, Kondo Y, Jelinek J, Shen L, Hartung H, Aplan PD, Czerniak BA, Liang S, Issa JP, Genome architecture marked by retrotransposons modulates predisposition to DNA methylation in cancer. Genome Res 20:10(1369-82)2010 Oct

20713525. Si J, Boumber YA, Shu J, Qin T, Ahmed S, He R, Jelinek J, Issa JP, Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Res 70:17(6968-77)2010 Sep 1

20606036. Kwabi-Addo B, Wang S, Chung W, Jelinek J, Patierno SR, Wang BD, Andrawis R, Lee NH, Apprey V, Issa JP, Ittmann M, Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. Clin Cancer Res 16:14(3539-47)2010 Jul 15

20182460. Cleyrat C, Jelinek J, Girodon F, Boissinot M, Ponge T, Harousseau JL, Issa JP, Hermouet S, JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5. Leukemia 24:5(1069-73)2010 May

20038729. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP, DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28:4(605-13)2010 Feb 1

19963934. Liang S, Lu Y, Jelinek J, Estecio M, Li H, Issa JP, Analysis of epigenetic modifications by next generation sequencing. Conf Proc IEEE Eng Med Biol Soc 2009:(6730)2009

19737982. Konishi K, Shen L, Jelinek J, Watanabe Y, Ahmed S, Kaneko K, Kogo M, Takano T, Imawari M, Hamilton SR, Issa JP, Concordant DNA methylation in synchronous colorectal carcinomas. Cancer Prev Res (Phila) 2:9(814-22)2009 Sep

19470736. Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II, Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 15:11(3881-8)2009 Jun 1

19441164. Tellez CS, Shen L, Estécio MR, Jelinek J, Gershenwald JE, Issa JP, CpG island methylation profiling in human melanoma cell lines. Melanoma Res 19:3(146-55)2009 Jun

19375421. Watanabe Y, Kim HS, Castoro RJ, Chung W, Estecio MR, Kondo K, Guo Y, Ahmed SS, Toyota M, Itoh F, Suk KT, Cho MY, Shen L, Jelinek J, Issa JP, Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology 136:7(2149-58)2009 Jun

18931345. Qin T, Jelinek J, Si J, Shu J, Issa JP, Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood 113:3(659-67)2009 Jan 15

18528427. Kuang SQ, Tong WG, Yang H, Lin W, Lee MK, Fang ZH, Wei Y, Jelinek J, Issa JP, Garcia-Manero G, Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 22:8(1529-38)2008 Aug

18523155. Kroeger H, Jelinek J, Estécio MR, He R, Kondo K, Chung W, Zhang L, Shen L, Kantarjian HM, Bueso-Ramos CE, Issa JP, Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 112:4(1366-73)2008 Aug 15

18446232. Chung W, Kwabi-Addo B, Ittmann M, Jelinek J, Shen L, Yu Y, Issa JP, Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One 3:4(e2079)2008 Apr 30

18055864. Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP, Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 111:4(2382-4)2008 Feb 15

18006804. Wang J, Bhutani M, Pathak AK, Lang W, Ren H, Jelinek J, He R, Shen L, Issa JP, Mao L, Delta DNMT3B variants regulate DNA methylation in a promoter-specific manner. Cancer Res 67:22(10647-52)2007 Nov 15

17976520. Jelinek J, Li J, Mnjoyan Z, Issa JP, Prchal JT, Afshar-Kharghan V, Epigenetic control of PRV-1 expression on neutrophils. Exp Hematol 35:11(1677-83)2007 Nov

17764565. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC Jr, Shen Y, Issa JP, Yu Y, Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 9:4(R57)2007

17634552. Qin T, Youssef EM, Jelinek J, Chen R, Yang AS, Garcia-Manero G, Issa JP, Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 13:14(4225-32)2007 Jul 15

17606710. Kwabi-Addo B, Chung W, Shen L, Ittmann M, Wheeler T, Jelinek J, Issa JP, Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res 13:13(3796-802)2007 Jul 1

17538160. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ, Mao L, Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25:16(2164-70)2007 Jun 1

17476321. Estécio MR, Gharibyan V, Shen L, Ibrahim AE, Doshi K, He R, Jelinek J, Yang AS, Yan PS, Huang TH, Tajara EH, Issa JP, LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One 2:5(e399)2007 May 2

17356406. Jelinek J, Issa JP, He R, Cmejla R, Cmejlova J, Pospisilova D, RPS19 and JAK2 genes are not silenced by DNA methylation in diamond blackfan anemia. J Pediatr Hematol Oncol 29:3(207-8)2007 Mar

17159988. Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N, Hsu K, Bloomfield CD, Stone RM, DeAngelo DJ, Galinsky IA, Issa JP, Clarke MF, Look AT, Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 13:1(78-83)2007 Jan

17110088. Kim J, Kim JY, Song KS, Lee YH, Seo JS, Jelinek J, Goldschmidt-Clermont PJ, Issa JP, Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in-vitro vascular senescence. Biochim Biophys Acta 1772:1(72-80)2007 Jan

16899610. Gollob JA, Sciambi CJ, Peterson BL, Richmond T, Thoreson M, Moran K, Dressman HK, Jelinek J, Issa JP, Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 12:15(4619-27)2006 Aug 1

16870548. Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian HM, Issa JP, Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica 91:8(1147-8)2006 Aug

16707430. Shu J, Jelinek J, Chang H, Shen L, Qin T, Chung W, Oki Y, Issa JP, Silencing of bidirectional promoters by DNA methylation in tumorigenesis. Cancer Res 66:10(5077-84)2006 May 15

Return to top